Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Excellent News
View:
Post by knoxt on Nov 06, 2023 7:27am

Excellent News

https://campaign-image.com/zohocampaigns/545854000002487005_outlined_theralase_logo_en.png

 

 

Theralase® (TSXV: TLT) has commenced a Listed Issuer Financing Exemption (“LIFE”) private placement financing for up to $CAN 5.3 M. Theralase(R) Announces Brokered LIFE Financing (tmx.com)

 

The Company is focused on providing the next standard of care treatment for bladder cancer (10th most common cancer in the world, 6th in men) which represents a potential market opportunity of approximately $USD 1 to 7 B annually. 

 

Why Theralase®

 

  • Theralase is developing a paradigm-shifting Photo Dynamic Therapy (“PDT”) for treating BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”).
  • On October 16th, the Company announced encouraging results with 65% of patients treated in the Phase-II pivotal trial achieving Complete Response (“CR”). Theralase(R) Provides Update on Bladder Cancer Clinical Study (tmx.com)
  • On October 23rd, the Company optimized the design of the Phase II clinical study. Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study (tmx.com)
  • The Company enrolled and treated 63 out of 100 patients in an FDA Phase II clinical study; potentially granting Theralase® access to a cancer market worth $USD 1 to 7 billion annually, if regulatory approved
  • Interim data to date is trending better than current FDA approved treatments, Keytruda® (Pembrolizumab) and Adstiladrin®
  • Theralase® expects to apply for pre-Breakthrough Therapy Designation (“BTD”) before year end.

 

 

Terms:

 

 

  • Offer: LIFE offering for up to $5.3mm, $0.22 per Unit (1 common share + 1 full 5 year warrant; exercisable at $0.28 for 5 years)
  • Best efforts to list the warrant

 

 

If you wish to participate, please e-mail rwhite@theralase.com to receive the Investor Questionnaire for completion.

 

Note: For US-based retail investors, the LIFE exemption would not apply and there would be a 4 month hold on the common shares and warrants.

 

Note: Unfortunately, Quebec-based investors are not eligible for this LIFE financing.

Comment by Legit62 on Nov 06, 2023 7:34am
whats the great news Knoxt?? were they able to fill it??
Comment by Eoganacht on Nov 06, 2023 8:53am
The great news is that Theralase has confirmed they will submit the BTD application before year end, they are now plainly stating that Ruvidar PDT is better than both FDA approved treatments Keytruda and Adstiladrin, and they treated one more patient. Just 37 patients to go.
Comment by riverrrow on Nov 06, 2023 9:21am
The great news is that it looks like the LIFE financing is still open and almost anyone can participate.  Normally in a pp you have to be an accredited investor with liquid assets of at least  one million dollars.  It looks like in the LIFE financing all us keyboard warriors can put our money where our mouths are.  There might be a $5,000 or $10,000 minimum, ask Roger.  ...more  
Comment by StevenBirch on Nov 06, 2023 9:42am
I was thinking (hoping?) this was a bone thrown to us regular folks after a few non-brokered PP's sold I assume to 'friends'. If so that could be a sign this is it for the cheap financings.
Comment by gonefishing2022 on Nov 06, 2023 9:44am
I Put in for 2500 Dollars 
Comment by Beano349 on Nov 06, 2023 9:47am
It said Pre BTD not just BTD so they pushed the timeliness again, although just slightly. 
Comment by N0taP00p on Nov 06, 2023 12:35pm
Eoganacht: You're one of the trusted voices here.  Did you mean pre-BTD submission or BTD submission by year end?  I'm not surprised if they pushed again without explicitly saying so. It's all moot if they can't raise money. 
Comment by BudFoxx2020 on Nov 06, 2023 12:53pm
Lol @ trusted voice.   There is a whole news release out today.  Just put in a little time to do some research and due dilligence.  Cheers.     https://stockhouse.com/opinion/interviews/2023/11/06/theralase-raising-up-to-5-3m-to-complete-bladder-cancer-study   Over the next six months the company is working on a pre-breakthrough designation approval for the ...more  
Comment by Eoganacht on Nov 06, 2023 1:02pm
It's pre-BTD submission by year end. I misread the email announcement.
Comment by 99942Apophis on Nov 06, 2023 1:23pm
Most of you already know progress of each new Pre-BTD brings us to where FDA  says yes its what we require please apply for BTD.  What we don’t know has that "final" Pre-BTD been sent or will it be sent in November,  perhaps the end of November update will give clarity, either way we all know it is near!
Comment by BudFoxx2020 on Nov 06, 2023 3:47pm
This is where the whole misunderstandings started today.   No where in the interview or email did the company confirmed they will submit BTD application before the end of the year.  In the interview RWD says they hope to have the Pre BTD submission in over the next 6 months and in the email the company said they EXPECT to apply for pre BTD before year end.  See how one post can ...more  
Comment by stocksnbonds458 on Nov 06, 2023 4:59pm
Eoganacht they haven't "confirmed" pre BTD  submission by December whatsoever, the wording was "expects to". This is the same expectation the company has had since July of this year, the process is a jungle of red tape and clinical trial rules/regulations that has slowed the process considerably. We will eventually get there, but man it takes patience!!
Comment by BudFoxx2020 on Nov 06, 2023 9:46am
Looks like the LIFE financing didn't even fill the minimum required.  This offering is supposed to close on the week of Oct 30.  The offering will only close if it meets the minimum required.  I am surprised RCC didn't just fill the rest themselves.  Only 3 million dollars, for a big player like RCC, that is chump change.  I mean RCC has a price target for TLT at 0 ...more  
Comment by N0taP00p on Nov 06, 2023 10:09am
What news are you all referring to. I don't see any NRs yet. 
Comment by Legit62 on Nov 06, 2023 10:14am
Same here NOtap00p
Comment by rhodiumd on Nov 06, 2023 10:33am
It wasn't an official NR.  Theralase sent out an email blast to their newsletter subscriber list earlier this morning . They basically sent the same content that was released via NR a couple weeks ago. Sign up to their newsletter on their website to receive the next ones.
Comment by N0taP00p on Nov 06, 2023 11:22am
Thanks Rhodium. I guess they are struggling to fill the minimum then.  This close and yet so far. At this point, I'm considering any kind of returns on this stock as a lucky lottery ticket, with a self reminder to never again invest in any Canadian startups without a lot more DD. SesenBio, Titan Medical, Sona Nanotech and a few others that i took a chance on. All great ideas. That's ...more  
Comment by Alamir1111 on Nov 06, 2023 11:57am
Tmd had a 5.66 $high. Sesn&sona 13$ high?did you sell early?
Comment by reconsider on Nov 06, 2023 11:58am
Excellent news would have been an already closed PP with 5M in the bank, not an email blast trying to lure newsletter subscribers. Not looking good... and now Q4 BTD submission turned into Pre-BTD... Neverending story.
Comment by Alamir1111 on Nov 06, 2023 12:05pm
Rdw is on market place interview 
Comment by Dumbeldorfwhite on Nov 06, 2023 12:34pm
Shhhh people around here don't want to hear it
Comment by rhodiumd on Nov 06, 2023 12:53pm
With inflation, market conditions, fears (wars and recession), and record household and credit card debt, the timing of the raise is definitely not perfect but it is what Theralase needs to bring this drug to market. They don't just have good numbers, they have best-in-class, record breaking efficacy and safety numbers. This will be the best drug on the market once it is commercialized.   ...more  
Comment by DeathXray33 on Nov 06, 2023 10:54am
Are any of you nice folks friends with Benny? If not, I wish him well...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250